The goal of this observational study is to evaluate the role of DTI-ALPS in the diagnostic and therapeutic management of NPH The main questions it aims to answer are: * Whether the glymphatic system (GS) is actually impaired in NPH * Whether DTI-ALPS index can predict the positive response to tap test (TT) and to ventriculo-peritoneal shunt (VPS) surgery. A healthy control group of patients (HC group) matched for age with the study group, will undergo MR with DTI-ALPS study
Enrolled patients followed a diagnostic-therapeutic pathway, consisting of the following steps: * t0: MR with DTI-ALPS study; * t1 (within 7 days from T0): clinical and neurosurgical assessment with NPH-specific rating scales (detailed below) before and after a lumbar TT, including measurements of opening pressure, drainage of 40-50 mL of CSF and collection of samples for neurodegenerative biomarkers (β-Amyloid 40, 42 total and P-Tau) quantification. An MR with DTI-ALPS study within 6 hours from TT; * t2 (within 3 months from T1): patients with a positive TT response (included responders, IR group) underwent VPS surgery, with CSF samples collected for the same neurodegenerative biomarkers (β-Amyloid 40, 42 total and P-Tau); * t3 (three months after surgery, IR group only): clinical and neurosurgical evaluation using NPH-specific rating scales to classify patients as improved, unchanged, or worsened compared to their preoperative condition; MR with DTI-ALPS study.
Study Type
OBSERVATIONAL
Enrollment
29
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy
Comparison between study and control group
Difference in DTI ALPS index between NPH patients and healthy controls
Time frame: 4 years
Difference in response to tap test between NPH patients who responded and those who did not
Difference in DTI ALPS index between NPH who responded to tap test (and underwent to ventircolopetoneal shunt) and those who did not
Time frame: 4 years
Change in DTI ALPS index across treatment in NPH patients
Difference in DTI ALPS index in NPH patients between T0 (before TT), T1 (after TT) and T3 (after VP shunt)
Time frame: 4 years
Change in CSF degenerative biomarker concentrations
CSF degenerative biomarkers (total tau protein, p-181 tau protein, Aβ42 e Aβ40 protein) variation between T1, T2 and T3
Time frame: 4 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.